The LEAP-10 phase III trial evaluated the efficacy of P plus lenvatinib (an oral multikinase inhibitor that targets vascular endothelial growth factor (VEGF) receptors 1, 2, and 3; fibroblast growth factor (FGF) receptors 1, 2, 3, and 4; platelet-derived growth factor receptor α (PDFGRα), RET, and KIT) vs. P plus placebo in 511 previously untreated CPS ≥1 R/M HNSCC patients, including 111 LSCC patients. Here, RET is linked to head and neck squamous cell carcinoma.